Pazdur’s Tale Of Two Targeted Therapies
Executive Summary
FDA’s oncology office director suggests Ariad’s ponatinib and ChemGenex’s Omapro represent the best and worst of times, respectively, in the quality of development programs for personalized medicines.
You may also be interested in...
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.
Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine
Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.